DE60130906D1 - Die synergistischen wirkungen von hgf und antibakterieller behandlung - Google Patents

Die synergistischen wirkungen von hgf und antibakterieller behandlung

Info

Publication number
DE60130906D1
DE60130906D1 DE60130906T DE60130906T DE60130906D1 DE 60130906 D1 DE60130906 D1 DE 60130906D1 DE 60130906 T DE60130906 T DE 60130906T DE 60130906 T DE60130906 T DE 60130906T DE 60130906 D1 DE60130906 D1 DE 60130906D1
Authority
DE
Germany
Prior art keywords
hgf
synergistic effects
ongoing
bacterial treatment
septicaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130906T
Other languages
English (en)
Other versions
DE60130906T2 (de
Inventor
Fariba Nayeri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Damavand Wound AB
Original Assignee
Damavand Wound AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003038A external-priority patent/SE0003038L/xx
Priority claimed from SE0101823A external-priority patent/SE0101823D0/xx
Application filed by Damavand Wound AB filed Critical Damavand Wound AB
Publication of DE60130906D1 publication Critical patent/DE60130906D1/de
Application granted granted Critical
Publication of DE60130906T2 publication Critical patent/DE60130906T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60130906T 2000-08-28 2001-08-28 Synergistische wirkungen von hgf und antibakterieller behandlung Expired - Lifetime DE60130906T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0003038A SE0003038L (sv) 2000-08-28 2000-08-28 Synergieffekter av HGF och antibakteriell behandling
SE0003038 2000-08-28
SE0101823A SE0101823D0 (sv) 2001-05-21 2001-05-21 Analysis of excrement with regard to hepatocyte growth factor
SE0101823 2001-05-21
PCT/SE2001/001831 WO2002017964A1 (en) 2000-08-28 2001-08-28 The synergetic effects of hgf and antibacterial treatment

Publications (2)

Publication Number Publication Date
DE60130906D1 true DE60130906D1 (de) 2007-11-22
DE60130906T2 DE60130906T2 (de) 2008-07-17

Family

ID=26655219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130906T Expired - Lifetime DE60130906T2 (de) 2000-08-28 2001-08-28 Synergistische wirkungen von hgf und antibakterieller behandlung

Country Status (7)

Country Link
US (2) US7601365B2 (de)
EP (3) EP1867996A1 (de)
AT (1) ATE375168T1 (de)
AU (1) AU2001284576A1 (de)
DE (1) DE60130906T2 (de)
ES (1) ES2295198T3 (de)
WO (1) WO2002017964A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
EP1661578B1 (de) * 2003-09-03 2018-03-14 Toshikazu Nakamura Mittel zur prävention und heilung von hautgeschwüren mit humanem rekombinantem hgf
DK1687636T3 (da) * 2003-09-29 2009-05-11 Peas Inst Ab Hurtig bestemmelse af forskellige former for hepatocytvækstfaktor (HGF) i legemsvæsker
JP2008516629A (ja) * 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
EP1957102B1 (de) * 2005-11-16 2012-01-18 Fariba Nayeri Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met-liganden und -hemmer
WO2011028173A1 (en) * 2009-09-05 2011-03-10 Fariba Nayeri Method of treatment of a patient suffering from an infection or injuries caused or complicated by infection
SE536400C2 (sv) 2012-02-22 2013-10-08 Peas Inst Ab Ny metod för snabb detektion av hepatocyttillväxtfaktor i biologiska vätskor
RU2597781C1 (ru) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики сальмонеллёзного гастроэнтерита и алкогольного гастроэнтерита
RU2597780C1 (ru) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики сальмонеллёзного гастроэнтерита и алкогольного гастроэнтерита
RU2716713C1 (ru) * 2019-08-01 2020-03-16 Федеральное государственное бюджетное учреждение науки Оренбургский федеральный исследовательский центр Уральского отделения Российской академии наук Способ диагностики стадии острого пиелонефрита

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176347A (en) * 1876-04-18 Improvement in filling packages with comb-honey
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
JP2750372B2 (ja) 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
JPH083195A (ja) 1991-10-04 1996-01-09 Toshiichi Nakamura 組織傷害治癒因子
JP3394982B2 (ja) 1991-11-07 2003-04-07 敏一 中村 ガン療法用副作用防止剤
WO1994004175A1 (en) 1992-08-24 1994-03-03 Toshikazu Nakamura Hgf production promoter
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
JP3962097B2 (ja) * 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
JP3818322B2 (ja) * 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
JP3477832B2 (ja) * 1994-07-22 2003-12-10 三菱化学株式会社 肝疾患の検出方法
US5656443A (en) * 1994-07-29 1997-08-12 Long Island Jewish Medical Center Method of diagnosing bladder cancer
JP3737532B2 (ja) 1994-08-19 2006-01-18 敏一 中村 軟骨障害治療剤
US6756358B2 (en) * 1994-08-19 2004-06-29 Sumitomo Pharmaceuticals Co., Ltd. Therapeutic agent for cartilaginous diseases
WO1996028475A1 (fr) * 1995-03-10 1996-09-19 Nakamura, Toshikazu Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol
JPH08268907A (ja) * 1995-03-31 1996-10-15 Sunstar Inc 歯周組織再生促進剤
JPH11507697A (ja) * 1995-06-09 1999-07-06 エヌ． ドロハン，ウィリアム キチンヒドロゲル、それらの製造方法及び利用
PT847757E (pt) 1995-08-29 2005-06-30 Anges Mg Inc Medicamento que compreende o gene de hgf
US5855918A (en) * 1995-09-12 1999-01-05 Genentech, Inc. Cystic fibrosis therapy
JP3832674B2 (ja) 1995-10-24 2006-10-11 敏一 中村 抗癌剤
US5827673A (en) * 1996-08-13 1998-10-27 Akira Matsumori Method of detecting myocardial infarction
JP4463885B2 (ja) 1996-12-05 2010-05-19 敏一 中村 劇症肝炎疾患治療剤
US6436388B2 (en) 1997-03-15 2002-08-20 Ikue Kudo Method of treating rhabdomyolysis by administering hepatocyte growth factor
CA2218145C (en) * 1997-04-14 2008-01-08 Toshikazu Nakamura Method of treating dilated cardiomyopathy
JP4094814B2 (ja) 1998-04-28 2008-06-04 敏一 中村 血管新生抑制剤
WO2001044294A2 (en) * 1999-12-15 2001-06-21 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation
JP5442173B2 (ja) 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
US7601365B2 (en) 2009-10-13
EP1840575A1 (de) 2007-10-03
ATE375168T1 (de) 2007-10-15
EP1320384A1 (de) 2003-06-25
WO2002017964A1 (en) 2002-03-07
US20100160223A1 (en) 2010-06-24
EP1867996A1 (de) 2007-12-19
DE60130906T2 (de) 2008-07-17
EP1320384B1 (de) 2007-10-10
US20040042968A1 (en) 2004-03-04
ES2295198T3 (es) 2008-04-16
AU2001284576A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
DE60119939D1 (de) Chinolinderivate als antibakterielle mittel
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
DK1284740T3 (da) Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
ATE340171T1 (de) Piperazinderivate zur behandlung bakterieller infektionen
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
TR200400072T4 (tr) Novel Biarylcarboxamides Biarylcarboxamide Nouveaux Biarylcarboxamides
DK174690A (da) Antibakterielle midler
ATE326525T1 (de) Bifidobakterium zur behandlung von entzündungskrankheiten
ATE344799T1 (de) Piperidinderivate als antibakterielle mittel
CY2011012I2 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
ATE314343T1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
DE60009511D1 (de) Nematizide trifluorbutene
CY1107609T1 (el) Απεικoνιση, διaγνωση και θεραπεiα ασθeνειας
TNSN03121A1 (en) Formes cristallines d'azithromycine
ATE346046T1 (de) Chinoline und deren in der 4-stellung durch eine piperazinhaltige gruppe substituierte nitrogenierte derivate und deren verwendung als antibakterielle mittel
DE60130906D1 (de) Die synergistischen wirkungen von hgf und antibakterieller behandlung
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
MA26289A1 (fr) Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales
ATE408618T1 (de) Synthetische peptidkonstrukte zur erkennung und behandlung von parodontose hervorgerufen durch porphyromonas gingivalis
ATE535284T1 (de) Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen
ATE514087T1 (de) Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneri
DE60218473D1 (de) Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition